This is a supplement to EyeWorld Magazine that doctors can take a test after reading and receive CME credits for.
Issue link: http://cmesupplements.eyeworld.org/i/706806
Advanced glaucoma treatment: Diagnostics, pharmaceuticals, and surgical options Supplement to EyeWorld August 2016 Supported by Aerie Pharmaceuticals, Alcon Laboratories, Allergan, and Bausch + Lomb Accreditation Statement This activity has been planned and imple- mented in accordance with the accreditation requirements and policies of the Accredi- tation Council for Continuing Medical Edu- cation through the joint providership of the American Society of Cataract & Refractive Surgery (ASCRS) and EyeWorld. ASCRS is ac- credited by the ACCME to provide continuing medical education for physicians. Designation Statement The American Society of Cataract & Refrac- tive Surgery designates this enduring materi- als educational activity for a maximum of 1.0 AMA PRA Category 1 Credits. ™ Physicians should claim only credit commensurate with the extent of their participation in the activity. Educational Objectives Ophthalmologists who participate in this activity will: • Identify the current baseline for safety, efficacy, and patient compliance with conventional therapies and discuss the impact of these levels on the manage- ment of the low-to-moderate glaucoma patient; • Assess the appropriate diagnostics for long-term glaucoma patient analysis and identify proper utilization of advanced features to identify progression; • Explain the patient compliance impact of newly available and emerging phar- maceutical regimens and the collateral changes they may have on treatment protocol efficacy; and • Describe the latest clinical data, proto- cols, appropriate patient candidates, and key surgical steps required to safely and effectively integrate MIGS technologies into practice. Claiming Credit To claim credit, participants may visit bit.ly/29GJ7YZ to review content and down- load the post-activity test and credit claim. All participants must pass the post-activity test with a score of 75% or higher to earn credit. Alternatively, the post-test form included in this supplement may be faxed to the number indicated for credit to be awarded, and a certificate will be mailed within 2 weeks. When viewing online or downloading the material, standard Internet access is required. Adobe Acrobat Reader is needed to view the materials. CME credit is valid through February 28, 2017. CME credit will not be awarded after that date. Notice of Off-Label Use Presentations This activity may include presentations on drugs or devices or uses of drugs or devices that may not have been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. ADA/Special Accommodations ASCRS and EyeWorld fully comply with the legal requirements of the Americans with Disabilities Act (ADA) and the rules and regulations thereof. Any participant in this educational program who requires special accommodations or services should contact Laura Johnson at email@example.com or 703-591-2220. Financial Interest Disclosures Ike Ahmed, MD, has received a retainer, ad hoc fees, or other consulting income from: Abbott Medical Optics, Accelerated Vision, Ace Vision Group, Ade Therapeutics, Aerie Pharmaceuticals, Alcon Laboratories, Allergan, AqueSys, Bausch + Lomb, Carl Zeiss Meditec, Clarity Medical Systems, Envisia Therapeutics, Eyelight, ForSight Labs, Glaukos Corporation, Iantech, InnFocus, Iridex, Ivantis, KeLo Tec, LayerBio, Leica Microsystems, Oculus, Omega Ophthalmics, Ono Pharma, PolyActiva, Sanoculis, Science Based Health, Transcend Medical, and TrueVision Systems. He has received research funding from AqueSys. Reay Brown, MD, has received a royalty or derives other financial gain from Glaukos and Rhein Medical. He has received research funding from Ivantis and Transcend Medical. Richard Lewis, MD, is a part-time employee of Aerie Pharmaceuticals. He has received a retainer, ad hoc fees, or other consulting income from: Alcon Laboratories, Allergan, AqueSys, AVS, Carl Zeiss Meditec, Envisia Therapeutics, Glaukos Corporation, Ivantis, Oculeve, PolyActiva, and ViSci. Nathan Radcliffe, MD, has received a retainer, ad hoc fees, or other consulting in- come from and is a member of the speakers bureaus of: Alcon Laboratories, Allergan, Carl Zeiss Meditec, Endo Optiks, Glaukos, Iridex, and Reichert. He has received a retainer, ad hoc fees, or other consulting income from Transcend Medical. Staff members: Laura Johnson has no ophthalmic-related financial interests. Beth Marsh has received a retainer ad hoc fees or other consulting income from Akorn and Shire. continued on page 2 This annual survey pro- vided additional information about members' clinical opinions and practice patterns regarding glaucoma management, draw- ing responses from more than 2,000 respondents. To help G laucoma is a significant problem among our pa- tient populations. The 2015 ASCRS Clinical Survey indicated that 30% of members see 50 or more patients with glaucoma each month (average: 41 patients). Panel discusses new developments in ophthalmology diagnostics and treatments by Reay Brown, MD The role of diagnostics, pharmaceuticals, and surgical choices in the pursuit of advanced glaucoma treatment Practice pearl: MIGS tech- nology is being adopted at a rapid rate. Comprehensive ophthalmologists are embrac- ing MIGS as a way to lower pressure or reduce eye drops in their glaucoma patients who need cataract surgery. This may be a paradigm shift because it shows that they are looking at MIGS as an alterna- tive to medical therapy. –Reay Brown, MD Figure 1. ASCRS members indicate their preferred therapy to add to a prostaglandin analog.